Idera Pharmaceuticals (NASDAQ:IDRA) will collaborate with AbbVie (NYSE:ABBV) on a three-arm Phase 1b open-label clinical trial evaluating combinations of an OX40 agonist (ABBV-368), a TLR-9 agonist (tilsotolimod), chemotherapy (nab-paclitaxel) and/or an anti-programmed cell death 1 (PD-1) antagonist (ABBV-181) stimulate the immune system resulting in anti-tumor responses.
AbbVie will conduct the study while Idera will supply tilsotolimod.
ABBV is up 1% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.